Why FishDiversity, Equity & InclusionPro Bono & Social ResponsibilityLegal OperationsPricingLegal Project ManagementKnowledge ManagementeDiscoveryLegal Technology ServicesOur PeopleServicesLitigationPatent LitigationTrademark, Copyright & Media LitigationTrade Secret LitigationAppellateITC Litigation & Section 337Standard Essential PatentsChancery & Corporate GovernancePost-GrantInter Partes ReviewPost-Grant ReviewEx Parte ReexaminationSupplemental ExaminationPatentPatent ProsecutionStrategic Patent Counseling & OpinionsPatent Portfolio ManagementUnitary Patent & Unified Patent CourtIP Licensing, Transactions & AgreementsTrademark & Copyright Counseling & ProsecutionStrategic Counseling, Registration & OpinionsAdvertising & MarketingDomain Names & InternetTTAB Oppositions & CancellationsDigital Millennium Copyright ActTransactions & AgreementsRegulatory & Government AffairsCommunications & Spectrum RegulationDrug & Medical Device RegulationmHealth & TelemedicinePrivacy & Data SecurityIndustriesElectrical & Computer TechnologySoftware & InternetHardwareSemiconductorsConsumer ElectronicsOpticsArtificial IntelligenceDigital HealthDigital Media & E-CommerceFinancial, Business & FinTech ServicesTelecommunicationsEnergy & ChemicalsPetrochemicalCleantechLife SciencesBiotech & DiagnosticsMedical DevicesPharmaceuticalsAcademic Research & Medical CentersTransportation, Aerospace & DefenseManufacturingAutonomous VehiclesInsightsThought LeadershipIP Law EssentialsPost-Grant Annual ReportsWebinarsPodcastsOfficesCareersNews & EventsContact UsHomeInsightsThought LeadershipGwilym J.O. AttwellMegan A. ChaconMadelyn McCormickJillian Shapiro, Ph.D.Evan T. Sumner, Ph.D.Lowering Drug Prices by Once Again Putting Americans FirstRegulatory & Government AffairsDrug & Medical Device RegulationLife SciencesPharmaceuticalsBlog
June 5, 2026
Hikma v. Amarin SCOTUS Decision
Fish & Richardson
Read moreBlog
March 9, 2026
Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments
Fish & Richardson
Read moreBlog
December 29, 2025
Lessons From Recent Pharma & Med Device Federal Circuit Decisions
Fish & Richardson
Read moreBlog
October 27, 2025
Lessons for Biopharma From the Battle of Entresto®
Fish & Richardson
Read moreArticle
July 11, 2025
IP Policy Shifts Are Promising for Patent Owners in High Tech
Bloomberg Law
Read moreBlog
May 23, 2025
HHS Sets Most-Favored-Nation Price Targets for Pharmaceuticals
Fish & Richardson
Read moreBlog
May 14, 2025
How Trump’s Latest Drug Price EO Could Impact Pharma
Fish & Richardson
Read moreBlog
March 18, 2025
Federal Circuit: PTE for Reissue Patents Should Be Calculated From Original Patent’s Issue Date
Fish & Richardson
Read moreBlog
February 24, 2025
Biologics and Biosimilars Landscape 2024: IP, Policy, and Market Developments
Fish & Richardson
Read moreBlog
February 18, 2025
How Startups Can Position Their IP Portfolios to Attract Investors
Fish & Richardson
Read moreBlog
June 5, 2026
Hikma v. Amarin SCOTUS Decision
Fish & Richardson
Read moreBlog
May 7, 2026
Teva v. Lilly: Conflicting Positions at PTAB and District Court Sink Patent Challenge
Fish & Richardson
Read moreBlog
March 9, 2026
Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments
Fish & Richardson
Read moreBlog
December 30, 2025
Court Declines To Lift 30-Month Stay To Prevent Alleged Unfair Competitive Advantage Between Generics
Fish & Richardson
Read moreBlog
December 30, 2025
UK High Court Clarifies Scope of SPC Waiver Notification Requirements
Fish & Richardson
Read moreBlog
December 29, 2025
Lessons From Recent Pharma & Med Device Federal Circuit Decisions
Fish & Richardson
Read moreBlog
October 27, 2025
Lessons for Biopharma From the Battle of Entresto®
Fish & Richardson
Read moreArticle
October 16, 2025
Biosimilars Litigation and Client Counseling
American Bar Association
Read moreBlog
October 16, 2025
District of Delaware Finds Use of Antibody Tech Protected by Safe Harbor
Fish & Richardson
Read moreBlog
October 3, 2025
District of Delaware Considers Scope of Injunction in Jazz v. Avadel Remand
Fish & Richardson
Read moreOfficesAtlantaAustinBostonChicagoDallasDelawareHoustonMinneapolisMunichNew YorkOrange CountySan DiegoShenzhenSilicon ValleyWashington, D.C.CareersLife at FishJudicial ClerksLaw StudentsLateral HiresScientists & EngineersOperations & Admin StaffTraining & BenefitsFAQSubscribeContact UsSite MapCookie PolicyDisclaimerPrivacy PolicyTerms of Use
Trump’s Drug Price Executive Order: What Drugmakers Should Know,AI智能索引,全网链接索引,智能导航,网页索引
- On April 15, 2025, President Trump issued an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.”